WO2011147810A1 - THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). - Google Patents

THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). Download PDF

Info

Publication number
WO2011147810A1
WO2011147810A1 PCT/EP2011/058433 EP2011058433W WO2011147810A1 WO 2011147810 A1 WO2011147810 A1 WO 2011147810A1 EP 2011058433 W EP2011058433 W EP 2011058433W WO 2011147810 A1 WO2011147810 A1 WO 2011147810A1
Authority
WO
WIPO (PCT)
Prior art keywords
systemic sclerosis
treatment
ssc
prevention
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/058433
Other languages
English (en)
French (fr)
Inventor
Claudia Hirth-Dietrich
Peter Sandner
Johannes-Peter Stasch
Andreas Knorr
Georges Von Degenfeld
Michael Hahn
Markus Follmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102010021637A external-priority patent/DE102010021637A1/de
Priority to SG2012085767A priority Critical patent/SG185690A1/en
Priority to EP11722786.8A priority patent/EP2576548B1/en
Priority to PL11722786T priority patent/PL2576548T3/pl
Priority to MX2012013574A priority patent/MX2012013574A/es
Priority to AU2011257336A priority patent/AU2011257336B2/en
Priority to PH1/2012/502322A priority patent/PH12012502322A1/en
Priority to RS20150600A priority patent/RS54261B1/sr
Priority to EA201291309A priority patent/EA030735B9/ru
Priority to HRP20150987TT priority patent/HRP20150987T1/hr
Priority to UAA201214901A priority patent/UA116521C2/uk
Priority to KR1020127033603A priority patent/KR101881174B1/ko
Priority to MA35392A priority patent/MA34249B1/fr
Priority to JP2013511644A priority patent/JP5883852B2/ja
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Priority to CA2800709A priority patent/CA2800709C/en
Priority to MEP-2015-147A priority patent/ME02207B/me
Priority to DK11722786.8T priority patent/DK2576548T3/en
Priority to US13/816,020 priority patent/US10189856B2/en
Priority to SI201130602T priority patent/SI2576548T1/sl
Priority to ES11722786.8T priority patent/ES2549979T3/es
Priority to NZ603799A priority patent/NZ603799A/en
Priority to CN201180036565.XA priority patent/CN103038232B/zh
Priority to HK13111320.3A priority patent/HK1183868B/xx
Publication of WO2011147810A1 publication Critical patent/WO2011147810A1/en
Priority to IL223128A priority patent/IL223128A/en
Priority to ZA2012/08824A priority patent/ZA201208824B/en
Priority to TNP2012000550A priority patent/TN2012000550A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • Fibrotic disorders addressed by therapeutic agents of the invention which in particular and with substantial advantage can be treated by the above mentioned sGC stimulators or sGC activators alone or in combination with PDE5 inhibitors comprise but are not limited to Systemic Sclerosis (SSc), Systemic Sclerosis (SSc) concomitant fibrosis and fibrotic diseases.
  • SSc Systemic Sclerosis
  • SSc Systemic Sclerosis
  • SSc Systemic Sclerosis refers to but is not limited to diffuse Systemic Sclerosis (dSSc), limited Systemic Sclerosis (ISSc), overlap type of Systemic Sclerosis, undifferentiated type of Systemic Sclerosis, Systemic Sclerosis sine scleroderma, skin fibrosis, scleroderma, nephrogenic fibrosing dermopathy (NFD), nephrogenic systemic fibrosis (NSF), keloid formation.
  • SSc concomitant fibrosis refers to fibrosis of internal organs, comprising but not limited to the gut, the lung, the kidney and the blood vessels.
  • Another preferred embodiment of the invention is the use for the production of a medicament for prevention and/or treatment of Systemic Sclerosis SSc concomitant fibrosis of internal organs, comprising the gut, the lung, the kidney and the blood vessels comprising an effective amount of a compound and/or a combination as indicated above.
  • Another preferred embodiment of the invention is the pharmaceutical formulation comprising at least one compound or one combination as indicated above for the use in the prevention and/or treatment of Systemic Sclerosis SSc concomitant fibrosis of internal organs, comprising the gut, the lung, the kidney and the blood vessels.
  • a pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration.
  • routes of administration include parenteral e.g., intravenous, intradermal, subcutaneous' oral (e.g.' inhalation)' transdermal (topical) transmucosal and rectal administration.
  • Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, a pharmaceutically acceptable polyol like glycerol, propylene glycol, liquid polyetheylene glycol, and suitable mixtures thereof.
  • the injected skin areas were fixed in 4% formalin and embedded in paraffin. Histological sections were stained with hematoxylin and eosin for the determination of dermal thickness.
  • the dermal thickness was determined by measuring the largest distance between the epidermal-dermal junction and the dermal-subcutaneous fat junction. The measurements were performed by an examiner blinded to the treatment of the mice.
  • hydroxyproline assay was performed. After digestion of punch biopsies (0 3mm) in 6M HC1 for three hours at 120°C, chloramine T (0.06 M) was added and samples were mixed and incubated for 20 min at room temperature. 3.15 M perchloric acid and 20 % p-dimethylaminobenzaldehyde were added and samples were incubated for additional 20 min at 60 °C. The absorbance was determined at 557 nm.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/EP2011/058433 2010-05-26 2011-05-24 THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc). Ceased WO2011147810A1 (en)

Priority Applications (25)

Application Number Priority Date Filing Date Title
HK13111320.3A HK1183868B (en) 2010-05-26 2011-05-24 The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc).
CA2800709A CA2800709C (en) 2010-05-26 2011-05-24 The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc)
PL11722786T PL2576548T3 (pl) 2010-05-26 2011-05-24 Zastosowanie stymulatorów sGC, aktywatorów sGC, pojedynczo i w kombinacjach z inhibitorami PDE5, w leczeniu twardziny układowej (SSc)
MX2012013574A MX2012013574A (es) 2010-05-26 2011-05-24 El uso de estimuladores de la sgc, activadores de la sgc, solos y en combinacion con inhibidores de la pde5 para el tratamiento de esclerosis sistemica (ecs).
AU2011257336A AU2011257336B2 (en) 2010-05-26 2011-05-24 The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc).
PH1/2012/502322A PH12012502322A1 (en) 2010-05-26 2011-05-24 The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc)
RS20150600A RS54261B1 (sr) 2010-05-26 2011-05-24 Upotreba sgc stimulatora, sgc aktivatora, pojedinačno i u kombinaciji sa pde5 inhibitorima za tretman sistemske skleroze (ssc)
EA201291309A EA030735B9 (ru) 2010-05-26 2011-05-24 ПРИМЕНЕНИЕ sGC СТИМУЛЯТОРОВ ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОГО СКЛЕРОЗА (SSc)
HRP20150987TT HRP20150987T1 (hr) 2010-05-26 2011-05-24 UPORABA sGC STIMULATORA, sGC AKTIVATORA, SAMOSTALNO I U KOMBINACIJAMA S INHIBITORIMA PDE5 ZA LIJEÄŚENJE SISTEMSKE SKLEROZE (SSc)
UAA201214901A UA116521C2 (uk) 2010-05-26 2011-05-24 Застосування sgc-стимуляторів, sgc-активаторів окремо і в комбінації з інгібіторами фде5 для лікування системної склеродермії (ssc)
KR1020127033603A KR101881174B1 (ko) 2010-05-26 2011-05-24 전신 경화증 （ＳＳｃ）의 치료를 위한 ｓＧＣ 자극제, ｓＧＣ 활성화제의 단독으로의 및 ＰＤＥ5 억제제와의 조합물의 용도
MA35392A MA34249B1 (fr) 2010-05-26 2011-05-24 Utilisation de stimulateurs de la sgc, d'activateurs de la sgc, seuls et en association avec des inhibiteurs de la pde5 en vue du traitement de la sclérodermie systémique
JP2013511644A JP5883852B2 (ja) 2010-05-26 2011-05-24 全身性強皮症（ＳＳｃ）を処置するためのｓＧＣ刺激剤、ｓＧＣアクチベーター単独およびＰＤＥ５阻害剤との組み合わせ剤の使用
SG2012085767A SG185690A1 (en) 2010-05-26 2011-05-24 THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc).
DK11722786.8T DK2576548T3 (en) 2010-05-26 2011-05-24 USE OF sGC stimulators, sGC activators alone and in combination with PDE5 inhibitors for treating systemic sclerosis (SSc)
ES11722786.8T ES2549979T3 (es) 2010-05-26 2011-05-24 El uso de estimuladores de la sGC, activadores de la sGC, solos y en combinaciones con inhibidores de la PDE5 para el tratamiento de esclerosis sistémica (EcS)
MEP-2015-147A ME02207B (me) 2010-05-26 2011-05-24 UPOTREBA sGC STIMULATORA, sGC AKTIVATORA, POJEDINAČNO I U KOMBINACIJI SA PDE5 INHIBITORIMA ZA TRETMAN SISTEMSKE SKLEROZE (SSc)
US13/816,020 US10189856B2 (en) 2010-05-26 2011-05-24 Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
SI201130602T SI2576548T1 (sl) 2010-05-26 2011-05-24 Uporaba sGC stimulatorjev, sGC aktivatorjev, samih in v kombinacijah s PDE5 inhibitorji za zdravljenje sistemske skleroze
EP11722786.8A EP2576548B1 (en) 2010-05-26 2011-05-24 THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc)
NZ603799A NZ603799A (en) 2010-05-26 2011-05-24 The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc).
CN201180036565.XA CN103038232B (zh) 2010-05-26 2011-05-24 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途
IL223128A IL223128A (en) 2010-05-26 2012-11-19 Use of sgc irritants, sgc operators alone and combinations with 5pde inhibitors for the treatment of systemic sclerosis
ZA2012/08824A ZA201208824B (en) 2010-05-26 2012-11-22 The use of sgc stimulators,sgc activators,alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc)
TNP2012000550A TN2012000550A1 (en) 2010-05-26 2012-11-23 THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc).

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102010021637.2 2010-05-26
DE102010021637A DE102010021637A1 (de) 2010-05-26 2010-05-26 Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP10170413.8 2010-07-22
EP10170413 2010-07-22

Publications (1)

Publication Number Publication Date
WO2011147810A1 true WO2011147810A1 (en) 2011-12-01

Family

ID=45003356

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/058433 Ceased WO2011147810A1 (en) 2010-05-26 2011-05-24 THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc).

Country Status (31)

Country Link
US (1) US10189856B2 (https=)
EP (1) EP2576548B1 (https=)
JP (1) JP5883852B2 (https=)
KR (1) KR101881174B1 (https=)
CN (1) CN103038232B (https=)
AU (1) AU2011257336B2 (https=)
CA (2) CA2955143C (https=)
CL (1) CL2012003281A1 (https=)
CR (1) CR20120597A (https=)
CY (1) CY1116703T1 (https=)
DK (1) DK2576548T3 (https=)
EA (1) EA030735B9 (https=)
ES (1) ES2549979T3 (https=)
HR (1) HRP20150987T1 (https=)
HU (1) HUE025162T2 (https=)
IL (1) IL223128A (https=)
MA (1) MA34249B1 (https=)
ME (1) ME02207B (https=)
MX (1) MX2012013574A (https=)
MY (1) MY170094A (https=)
NZ (1) NZ603799A (https=)
PH (1) PH12012502322A1 (https=)
PL (1) PL2576548T3 (https=)
PT (1) PT2576548E (https=)
RS (1) RS54261B1 (https=)
SG (1) SG185690A1 (https=)
SI (1) SI2576548T1 (https=)
TN (1) TN2012000550A1 (https=)
UA (1) UA116521C2 (https=)
WO (1) WO2011147810A1 (https=)
ZA (1) ZA201208824B (https=)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013086935A1 (zh) * 2011-12-12 2013-06-20 南京药石药物研发有限公司 1-（2-氟苄基）-1H -吡唑并[3，4- b]吡啶-3 -甲脒盐酸盐的合成方法
EP2594270A3 (en) * 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
WO2014047325A1 (en) * 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
JP2015509515A (ja) * 2012-03-06 2015-03-30 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換アザ二環およびその使用
US9061030B2 (en) 2010-11-09 2015-06-23 Ironwood Pharmaceuticals, Inc. sGC stimulators
WO2015106268A1 (en) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US9139564B2 (en) 2011-12-27 2015-09-22 Ironwood Pharmaceuticals, Inc. 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators
US9353090B2 (en) 2014-07-22 2016-05-31 Boehringer Ingelheim International Gmbh Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
WO2016177660A1 (en) 2015-05-06 2016-11-10 Bayer Pharma Aktiengesellschaft The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
MD4425C1 (ro) * 2012-09-07 2017-01-31 Boehringer Ingelheim International Gmbh Alcoxipirazoli în calitate de activatori ai guanilat-ciclazei solubile
WO2017106175A2 (en) 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
US9714213B2 (en) 2013-10-15 2017-07-25 Toa Eiyo Ltd. 4-aminomethylbenzoic acid derivative
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
AU2014236719B2 (en) * 2013-03-15 2018-06-21 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
CN108367165A (zh) * 2015-10-07 2018-08-03 汤丹霞 治疗皮肤纤维化病症的组合物和方法
US10208018B2 (en) 2014-07-02 2019-02-19 Novartis Ag Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
US10316020B2 (en) 2015-12-18 2019-06-11 Novartis Ag Indane derivatives and the use thereof as soluble guanylate cyclase activators
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
WO2020014504A1 (en) 2018-07-11 2020-01-16 Cyclerion Therapeutics, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS
US12138252B2 (en) 2017-02-12 2024-11-12 Aiviva Biopharma, Inc. Multikinase inhibitors of VEGF and TGF beta and uses thereof
US12502391B2 (en) 2018-08-15 2025-12-23 Aiviva Biopharma, Inc. Multi-kinase inhibitors of VEGF and TGF beta and uses thereof
US12600715B2 (en) 2022-11-04 2026-04-14 Boehringer Ingelheim International Gmbh Soluble guanylate cyclate activators for treating systemic sclerosis

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2576548T1 (sl) 2010-05-26 2015-11-30 Adverio Pharma Gmbh Uporaba sGC stimulatorjev, sGC aktivatorjev, samih in v kombinacijah s PDE5 inhibitorji za zdravljenje sistemske skleroze
DE102010021637A1 (de) * 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
CN105102457A (zh) 2013-02-21 2015-11-25 阿德弗里奥药品有限责任公司 {4,6-二氨基-2-[1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式
EP3024455A1 (en) 2013-07-25 2016-06-01 Bayer Pharma Aktiengesellschaft Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis
JP6557684B2 (ja) 2014-06-13 2019-08-07 インベンティバ 線維性疾患の治療に用いられるｐｐａｒ化合物
WO2017013010A1 (de) * 2015-07-23 2017-01-26 Bayer Pharma Aktiengesellschaft Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung
BR112018015718A2 (pt) 2016-02-01 2019-01-08 Ironwood Pharmaceuticals Inc utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash)
JP7090639B2 (ja) 2017-04-11 2022-06-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッド フッ素置換されたインダゾール化合物及びその使用
CN108690016B (zh) * 2017-04-11 2022-08-12 广东东阳光药业有限公司 吡唑并吡啶类化合物及其用途
CN111638329B (zh) * 2020-06-09 2021-06-01 南方医科大学 一种用于检测布鲁氏菌病elispot检测试剂盒及其应用
EP3925953A1 (en) * 2020-06-16 2021-12-22 Adverio Pharma GmbH Process for preparing methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
CN115160312B (zh) * 2022-06-29 2023-12-26 常州制药厂有限公司 一种维立西呱关键中间体及其制备方法
KR102831482B1 (ko) * 2022-11-04 2025-07-07 한국타이어앤테크놀로지 주식회사 차량용 타이어의 젖은 노면 제동성능 측정방법
CN117462685A (zh) * 2023-04-14 2024-01-30 北京悦康科创医药科技股份有限公司 Pde5抑制剂或其组合物在制备用于治疗泌尿系统疾病药物中的用途

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016223A1 (de) * 1996-10-14 1998-04-23 Bayer Aktiengesellschaft Verwendung von 1-benzyl-3-(substituiertes-hetaryl)-kondensierten pyrazol-derivaten zur belandlung von speziellen erkrankungen des herz-kreislaufsystems und des zentralnervensystems
WO2000006568A1 (de) 1998-07-29 2000-02-10 Bayer Aktiengesellschaft Substituierte pyrazolderivate
WO2000006569A1 (de) 1998-07-29 2000-02-10 Bayer Aktiengesellschaft Mit sechsgliedrigen heterocyclischen ringen kondensierte substituierte pyrazolderivate
DE19943635A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
WO2002042301A1 (de) 2000-11-22 2002-05-30 Bayer Aktiengesellschaft Neue pyridin-substituierte pyrazolopyridinderivate
WO2002067851A2 (en) * 2000-12-29 2002-09-06 Alteon, Inc. Method for treating fibrotic diseases or other indications iiic
WO2003095451A1 (de) 2002-05-08 2003-11-20 Bayer Healthcare Ag Carbamat-substituierte pyrazolopyridine
WO2009032249A1 (en) 2007-09-06 2009-03-12 Merck & Co., Inc. Soluble guanylate cyclase activators
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
WO2009071504A1 (en) 2007-12-03 2009-06-11 Smithkline Beecham Corporation 2,6-disubstituted pyridines as soluble guanylate cyclase activators
WO2009123316A1 (ja) 2008-04-04 2009-10-08 武田薬品工業株式会社 複素環誘導体及びその用途
US20090286782A1 (en) * 2008-05-19 2009-11-19 Ibrahim Prabha N Compounds and methods for kinase modulation, and indications therefor
WO2010031791A1 (en) * 2008-09-16 2010-03-25 Biovitrum Ab (Publ) New compounds ii
WO2010065275A1 (en) 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380945A (en) 1989-06-21 1995-01-10 Abbott Laboratories Guanidino compounds as regulators of nitric oxide synthase
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
CN1332943C (zh) 1998-07-08 2007-08-22 萨诺费－阿文蒂斯德国有限公司 硫取代的磺酰基氨基羧酸n－芳基酰胺,其制备方法、用途以及含有该化合物的药物制剂
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
US6538023B1 (en) 2000-09-15 2003-03-25 Tsuyoshi Ohnishi Therapeutic uses of green tea polyphenols for sickle cell disease
DE10054278A1 (de) * 2000-11-02 2002-05-08 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Osteoporose
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
GB0202254D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Prevention of scarring
US20050267032A1 (en) 2004-05-21 2005-12-01 Icagen, Inc. Sulfone-containing prodrugs
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005016345A1 (de) 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005047945A1 (de) * 2005-07-16 2007-01-18 Bayer Healthcare Ag Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Raynaud Phänomenen
BRPI0614001A2 (pt) 2005-07-18 2011-03-01 Bayer Healthcare Ag uso de ativadores e estimuladores de guanilato ciclase solúvel para a prevenção ou tratamento de distúrbios renais
WO2008138483A1 (en) 2007-05-12 2008-11-20 Bayer Schering Pharma Aktiengesellschaft sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS
DE102007026392A1 (de) 2007-06-06 2008-12-11 Bayer Healthcare Ag Lösungen für die Perfusion und Konservierung von Organen und Geweben
EP2387404B1 (en) 2009-01-17 2014-06-25 Bayer Intellectual Property GmbH Sgc stimulators and activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
DK2421519T3 (en) 2009-04-23 2017-02-06 Univ Zuerich NMDA RECEPTOR BLOCKERS FOR THE TREATMENT OF SEAL CELL ANAEMS
AU2010330813B2 (en) * 2009-12-18 2016-04-28 Exodos Life Sciences Limited Partnership Methods and compositions for treating peripheral vascular disease
SI2531187T1 (sl) 2010-02-05 2016-01-29 Adverio Pharma Gmbh Stimulatorji sGC ali aktivatorji sGC sami in v kombinaciji z inhibitorji PDE5 za zdravljenje cistične fibroze
SI2576548T1 (sl) 2010-05-26 2015-11-30 Adverio Pharma Gmbh Uporaba sGC stimulatorjev, sGC aktivatorjev, samih in v kombinacijah s PDE5 inhibitorji za zdravljenje sistemske skleroze

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016223A1 (de) * 1996-10-14 1998-04-23 Bayer Aktiengesellschaft Verwendung von 1-benzyl-3-(substituiertes-hetaryl)-kondensierten pyrazol-derivaten zur belandlung von speziellen erkrankungen des herz-kreislaufsystems und des zentralnervensystems
WO2000006568A1 (de) 1998-07-29 2000-02-10 Bayer Aktiengesellschaft Substituierte pyrazolderivate
WO2000006569A1 (de) 1998-07-29 2000-02-10 Bayer Aktiengesellschaft Mit sechsgliedrigen heterocyclischen ringen kondensierte substituierte pyrazolderivate
DE19943635A1 (de) * 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
WO2001019780A2 (de) 1999-09-13 2001-03-22 Bayer Aktiengesellschaft Neuartige aminodicarbonsäurederivate mit pharmazeutischen eigenschaften
WO2002042301A1 (de) 2000-11-22 2002-05-30 Bayer Aktiengesellschaft Neue pyridin-substituierte pyrazolopyridinderivate
WO2002067851A2 (en) * 2000-12-29 2002-09-06 Alteon, Inc. Method for treating fibrotic diseases or other indications iiic
WO2003095451A1 (de) 2002-05-08 2003-11-20 Bayer Healthcare Ag Carbamat-substituierte pyrazolopyridine
WO2009032249A1 (en) 2007-09-06 2009-03-12 Merck & Co., Inc. Soluble guanylate cyclase activators
WO2009068652A1 (en) 2007-11-30 2009-06-04 Smithkline Beecham Corporation 2, 6-disubstituted pyridines and 2, 4-disubstituted pyrimidines as soluble guanylate cyclase activators
WO2009071504A1 (en) 2007-12-03 2009-06-11 Smithkline Beecham Corporation 2,6-disubstituted pyridines as soluble guanylate cyclase activators
WO2009123316A1 (ja) 2008-04-04 2009-10-08 武田薬品工業株式会社 複素環誘導体及びその用途
US20090286782A1 (en) * 2008-05-19 2009-11-19 Ibrahim Prabha N Compounds and methods for kinase modulation, and indications therefor
WO2010031791A1 (en) * 2008-09-16 2010-03-25 Biovitrum Ab (Publ) New compounds ii
WO2010065275A1 (en) 2008-11-25 2010-06-10 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators

Non-Patent Citations (25)

* Cited by examiner, † Cited by third party
Title
EVGENOV ET AL., NAT. REV. DRUG. DISCOV., vol. 5, no. 9, 2006, pages 755 - 768
EVGENOV OV, PACHER P, SCHMIDT PM ET AL.: "NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential", NAT. REV. DRUG. DISCOV., vol. 5, no. 9, 2006, pages 755 - 68
FERRINI ET AL., B. J. UROL., vol. 97, 2006, pages 625 - 633
FERRINI MG, KOVANECZ I, NOLAZCO G: "Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model ofPeyronie's disease", B. J. U., vol. 97, 2006, pages 625 - 633
HARRIS ED ET AL.: "Kelley's Textbook of Rhematology", 2005, ELSEVIER SAUNDERS
HARRIS ET AL.: "Kelley's Textbook of Rhematology", 2005, ELSEVIER SAUNDERS
HELVETICA CHIMICA ACTA, vol. 34, 1951, pages 835 - 40
J UROL., vol. 177, pages 1401 - 1407
KAPLAN SA, GONZALEZ RR: "Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms", REV. UROL., vol. 9, no. 2, 2007, pages 73 - 77
KAPLAN, GONZALEZ, REV. UROL., vol. 9, 2007, pages 73 - 77
KHANNA D, DENTON CP: "Evidence-based management of rapidly progressing systemic sclerosis", BEST. PRACT. RES. CLIN. RHEUMATOL., vol. 24, 2010, pages 387 - 400
KHANNA, DENTON, BEST. PRACT. RES. CLIN. RHEUMATOL., vol. 24, 2010, pages 387 - 400
KNORR A, HIRTH-DIETRICH C, ALONSO-ALIJA C. ET AL.: "Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis", ARZNEIMITTELFORSCHUNG, vol. 58, 2008, pages 71 - 80
KNORR ET AL., ARZNEIMITTELFORSCHUNG, vol. 58, 2008, pages 71 - 80
MCVARY ET AL., J. UROL., vol. 177, 2007, pages 1071 - 1077
MCVARY KT, ROEHRBORN CG, KAMINETSKY JC, AUERBACH SM, WACHS B, YOUNG JM, ESLER A, SIDES GD, DENES BS.: "Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia", J UROL., vol. 177, 2007, pages 1401 - 1407
MVARY K K. T. MCVARY, W. MONNIG, J. L. CAMPS, JR., J. M. YOUNG, L. J. TSENG, G. VAN DEN ENDE: "Sildenafil citrate improves erectile function and ur inary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial", J. UROL., vol. 177, 2007, pages 1071 - 1077
ONG VH, DENTON CP: "Innovative therapies for systemic sclerosis", CURR. OPIN. RHEUMATOL., vol. 22, 2010, pages 264 - 272
ONG, DENTON, CURR. OPIN. RHEUMATOL., vol. 22, 2010, pages 264 - 272
PORST ET AL., CURR. UROL. REP., vol. 9, 2008, pages 295 - 301
PORST H, SANDNER P, ULBRICH E.: "Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia", CURR. UROL. REP., vol. 9, 2008, pages 295 - 301
SANDNER ET AL.: "Handbook Exper. Pharmacol.", vol. 191, 2009, pages: 507 - 531
SANDNER P, NEUSER D, BISCHOFF E: "Handb. Exp. Pharmacol.", vol. 191, 2009, article "Erectile dysfunction and lower urinary tract.", pages: 507 - 531
SPIERA R, GORDON J, MERSTEN J, MAGRO C, MEHTA M, WILDMANN H, KLOIBER S, KIROU K, LYMAN S, CROW M: "Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a lyear, phse IIa, single-arm open-label clinical trial.", ANN. RHEUM. DIS., 11 March 2011 (2011-03-11)
SPIERA, ANN. RHEUM. DIS., March 2011 (2011-03-01)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9061030B2 (en) 2010-11-09 2015-06-23 Ironwood Pharmaceuticals, Inc. sGC stimulators
EP2594270A3 (en) * 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
WO2013086935A1 (zh) * 2011-12-12 2013-06-20 南京药石药物研发有限公司 1-（2-氟苄基）-1H -吡唑并[3，4- b]吡啶-3 -甲脒盐酸盐的合成方法
US8957210B2 (en) 2011-12-12 2015-02-17 Pharmablock (Nanjing) R&D Co., Ltd. Method for synthesizing 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-formamidine hydrochloride
US9139564B2 (en) 2011-12-27 2015-09-22 Ironwood Pharmaceuticals, Inc. 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators
JP2015509515A (ja) * 2012-03-06 2015-03-30 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換アザ二環およびその使用
MD4425C1 (ro) * 2012-09-07 2017-01-31 Boehringer Ingelheim International Gmbh Alcoxipirazoli în calitate de activatori ai guanilat-ciclazei solubile
USRE46886E1 (en) 2012-09-07 2018-06-05 Boehringer Ingelheim International Gmbh Alkoxy pyrazoles as soluble guanylate cyclase activators
WO2014047325A1 (en) * 2012-09-19 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US9487508B2 (en) 2012-09-19 2016-11-08 Ironwood Pharmaceuticals, Inc. SGC stimulators
US11045476B2 (en) 2013-03-15 2021-06-29 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US10500210B2 (en) 2013-03-15 2019-12-10 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
AU2014236719B2 (en) * 2013-03-15 2018-06-21 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
US9714213B2 (en) 2013-10-15 2017-07-25 Toa Eiyo Ltd. 4-aminomethylbenzoic acid derivative
WO2015106268A1 (en) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
US10208018B2 (en) 2014-07-02 2019-02-19 Novartis Ag Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
US10550102B2 (en) 2014-07-02 2020-02-04 Novartis Ag Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
US9353090B2 (en) 2014-07-22 2016-05-31 Boehringer Ingelheim International Gmbh Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
WO2016177660A1 (en) 2015-05-06 2016-11-10 Bayer Pharma Aktiengesellschaft The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
US20180169095A1 (en) * 2015-05-06 2018-06-21 Bayer Pharma Aktiengesellschaft The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
EP3359258A4 (en) * 2015-10-07 2019-08-21 AiViva Biopharma, Inc. COMPOSITIONS AND METHOD FOR THE TREATMENT OF FIBROTIC SKIN DISEASES
CN108367165A (zh) * 2015-10-07 2018-08-03 汤丹霞 治疗皮肤纤维化病症的组合物和方法
US10736885B2 (en) 2015-10-07 2020-08-11 Aiviva Biopharma, Inc. Compositions and methods of treating dermal fibrotic disorders
WO2017106175A2 (en) 2015-12-14 2017-06-22 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
US10316020B2 (en) 2015-12-18 2019-06-11 Novartis Ag Indane derivatives and the use thereof as soluble guanylate cyclase activators
WO2018111795A2 (en) 2016-12-13 2018-06-21 Ironwood Pharmaceuticals, Inc. Use of sgc stimulators for the treatment of esophageal motility disorders
US12138252B2 (en) 2017-02-12 2024-11-12 Aiviva Biopharma, Inc. Multikinase inhibitors of VEGF and TGF beta and uses thereof
EP3574905A1 (en) 2018-05-30 2019-12-04 Adverio Pharma GmbH Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
WO2020014504A1 (en) 2018-07-11 2020-01-16 Cyclerion Therapeutics, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS
US12502391B2 (en) 2018-08-15 2025-12-23 Aiviva Biopharma, Inc. Multi-kinase inhibitors of VEGF and TGF beta and uses thereof
US12600715B2 (en) 2022-11-04 2026-04-14 Boehringer Ingelheim International Gmbh Soluble guanylate cyclate activators for treating systemic sclerosis

Also Published As

Publication number Publication date
IL223128A (en) 2016-05-31
EP2576548A1 (en) 2013-04-10
PH12012502322A1 (en) 2016-06-10
UA116521C2 (uk) 2018-04-10
HK1183868A1 (zh) 2014-01-10
AU2011257336B2 (en) 2015-11-19
RS54261B1 (sr) 2016-02-29
DK2576548T3 (en) 2015-09-28
MY170094A (en) 2019-07-05
US10189856B2 (en) 2019-01-29
EA030735B9 (ru) 2019-02-28
JP2013526598A (ja) 2013-06-24
KR20130116001A (ko) 2013-10-22
CN103038232B (zh) 2016-01-20
PT2576548E (pt) 2015-09-16
CA2955143A1 (en) 2011-12-01
CL2012003281A1 (es) 2013-05-17
PL2576548T3 (pl) 2015-11-30
CA2800709A1 (en) 2011-12-01
SI2576548T1 (sl) 2015-11-30
HRP20150987T1 (hr) 2015-10-23
SG185690A1 (en) 2012-12-28
CY1116703T1 (el) 2017-03-15
EA201291309A1 (ru) 2013-06-28
TN2012000550A1 (en) 2014-04-01
AU2011257336A1 (en) 2012-12-20
CR20120597A (es) 2013-03-11
EA030735B1 (ru) 2018-09-28
ES2549979T3 (es) 2015-11-03
CN103038232A (zh) 2013-04-10
HUE025162T2 (en) 2016-04-28
MX2012013574A (es) 2013-01-24
KR101881174B1 (ko) 2018-07-23
ME02207B (me) 2016-02-20
CA2800709C (en) 2017-04-04
ZA201208824B (en) 2014-01-29
MA34249B1 (fr) 2013-05-02
JP5883852B2 (ja) 2016-03-15
CA2955143C (en) 2020-02-11
NZ603799A (en) 2014-10-31
US20140038956A1 (en) 2014-02-06
IL223128A0 (en) 2013-02-03
EP2576548B1 (en) 2015-06-24

Similar Documents

Publication Publication Date Title
CA2800709C (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc)
US9284284B2 (en) Oxazine derivatives and their use in the treatment of disease
JP5823657B1 (ja) ドーパミンｄ１リガンドとしての複素芳香族化合物
JP7055528B1 (ja) プロテアーゼ阻害剤としてのケトアミド誘導体
US20150210705A1 (en) Substituted pyrrolopyridines and pyrrolopyrazines for treating cancer or inflammatory diseases
CN105085482B (zh) 取代的哌嗪化合物及其使用方法和用途
CA3250517A1 (en) CHEMICAL ENTITIES, COMPOSITIONS AND PROCESSES
US12331054B2 (en) Perk inhibiting imidazolopyrazine compounds
JP2022511112A (ja) Ａｌｋ５阻害剤としてのナフチリジンおよびキノリン誘導体
ES2775674T3 (es) Compuestos de 6,7-dihidro-5H-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
US10316038B2 (en) Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer
EP3728247B1 (en) Oxadiazole derivatives as rho-kinase inhibitors
EP3728248B1 (en) Azaindole derivatives as rho-kinase inhibitors
WO2022135534A1 (zh) 取代的含氮双环化合物及其用途
HK1183868B (en) The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc).
US20250059175A1 (en) Mutant Pi3k-Alpha Inhibitors And Their Use As Pharmaceuticals
AU2024310014A1 (en) IMIDAZO[1,2-α]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180036565.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11722786

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 223128

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2013511644

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2012/013574

Country of ref document: MX

Ref document number: 2011722786

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2800709

Country of ref document: CA

Ref document number: 0170912

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 2012003281

Country of ref document: CL

Ref document number: 12012502322

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: DZP2012000801

Country of ref document: DZ

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1201006117

Country of ref document: TH

Ref document number: CR2012-000597

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2011257336

Country of ref document: AU

Date of ref document: 20110524

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201291309

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20127033603

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201214901

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 13816020

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012029826

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: P-2015/0600

Country of ref document: RS

ENP Entry into the national phase

Ref document number: 112012029826

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20121123